H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aligos Therapeutics (ALGS – Research Report) today and set a price target of $70.00.
Ed Arce has given his Buy rating due to a combination of factors, primarily centered around the promising data presented by Aligos Therapeutics at the APASL 2025 conference. The company’s lead program, ALG-000184, demonstrated sustained antiviral activity in both HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) patients, showcasing its potential as a first-line therapy for long-term viral suppression.
Additionally, the data indicated that ALG-000184 maintained a favorable safety profile over an extended treatment period of up to 96 weeks. The initiation of a Phase 2 study for ALG-000184 in mid-2025 is seen as a significant milestone for Aligos. Furthermore, the potential of ALG-055009 to reduce liver fat in patients on stable GLP-1 agonist therapy adds to the positive outlook for the company’s pipeline. These factors collectively support the Buy rating, reflecting confidence in Aligos’ strategic direction and clinical progress.